Streamex (STEX) Announces Public Offering of Common Stock, Shares Up 12.34%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Public Offering Announcement: Streamex has announced its intention to conduct an underwritten public offering of common stock, although specific size and terms remain undisclosed, indicating a proactive approach towards capital markets that is expected to support future growth.
- Clear Use of Proceeds: The company plans to utilize the net proceeds for repaying prior indebtedness and for working capital and general corporate purposes, which will help improve its financial condition and enhance operational flexibility.
- Underwriter Selection: Needham & Company and Siebert have been appointed as joint book-running managers for the offering, reflecting the company's focus on professionalism and market influence in ensuring the success of the issuance.
- Positive Stock Reaction: Following the announcement, Streamex's shares rose by 12.34%, indicating market optimism regarding the company's future financing plans, which may further bolster investor confidence.
Analyst Views on STEX
Wall Street analysts forecast STEX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STEX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.080
Low
12.00
Averages
12.00
High
12.00
Current: 3.080
Low
12.00
Averages
12.00
High
12.00
About STEX
Streamex Corp., formerly BioSig Technologies, Inc., is a real world asset (RWA) tokenization company. The Company with institutional grade infrastructure brings the gold and commodities market on chain, enabled by a gold denominated treasury and tokenization technology powering the modern commodities market. The Company is a wholly owned subsidiary of BioSig Technologies, Inc.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








